domains/health/CMS 2027 chart review exclusion targets vertical integration profit arbitrage by removing upcoded diagnoses from MA risk scoring.md

@@ -34,6 +34,12 @@ The broader 2027 rate environment compounds the pressure into a three-pronged sq
 
 This is a proxy inertia story. Since [[proxy inertia is the most reliable predictor of incumbent failure because current profitability rationally discourages pursuit of viable futures]], the incumbents who built their MA economics around coding optimization will struggle to shift toward genuine quality competition. The plans that never relied on coding arbitrage (Devoted, Alignment, Kaiser) are better positioned.
 
+
+### Additional Evidence (extend)
+*Source: [[2026-02-01-cms-2027-advance-notice-ma-rates]] | Added: 2026-03-11 | Extractor: anthropic/claude-sonnet-4.5*
+
+The 2027 Advance Notice provides full implementation details and broader reform context: CMS proposes excluding ALL diagnoses from unlinked chart review records (not tied to documented service), with diagnoses from chart reviews allowed only if tied to actual medical encounter. Projected savings exceed $7 billion in 2027. This is explicitly described as 'the most targeted reform to date against retrospective code-mining.' Critically, the chart review exclusion does not operate in isolation. It coincides with V28 completion (2026 is final phase-in year, 2027 recalibration uses 2023 diagnoses and 2024 expenditures) and flat baseline rates providing no growth cushion. This three-way convergence creates the first sustained compression of MA economics since BBA 1997, with industry warning of benefit cuts and market exits. Purpose-built MA plans with lower coding intensity are explicitly positioned as better-positioned to survive than acquisition-based vertical integration models.
+
 ---
 
 Relevant Notes:

domains/health/Devoted is the fastest-growing MA plan at 121 percent growth because purpose-built technology outperforms acquisition-based vertical integration during CMS tightening.md

@@ -23,6 +23,12 @@ Devoted was built from scratch on the Orinoco platform — a unified AI-native o
 
 Since [[proxy inertia is the most reliable predictor of incumbent failure because current profitability rationally discourages pursuit of viable futures]], UnitedHealth's $9 billion annual technology spend directed at optimizing existing infrastructure (consolidating 18 EMRs, AI scribing within legacy workflows) rather than rebuilding around prevention is textbook proxy inertia. The margin from coding arbitrage rationally prevents pursuit of the purpose-built alternative.
 
+
+### Additional Evidence (confirm)
+*Source: [[2026-02-01-cms-2027-advance-notice-ma-rates]] | Added: 2026-03-11 | Extractor: anthropic/claude-sonnet-4.5*
+
+The 2027 Advance Notice confirms the structural advantage thesis of purpose-built plans during regulatory tightening. Industry response to the combined chart review exclusion, V28 completion, and flat rates shows insurers warning of benefit cuts and market exits. The notice explicitly states that 'purpose-built MA plans (lower coding intensity, genuine care delivery) are better positioned than acquisition-based plans' to survive the compression. This validates the Devoted growth thesis: as CMS tightens coding enforcement and removes the arbitrage opportunities that acquisition-based vertical integration models depend on, purpose-built plans with genuine care delivery infrastructure and lower coding intensity should outperform. The 2027 reforms represent the regulatory environment intensifying exactly as the Devoted thesis predicts.
+
 ---
 
 Relevant Notes:

domains/health/cms-2027-advance-notice-creates-structural-inflection-for-ma-through-chart-review-exclusion-v28-completion-and-flat-rates.md

@@ -0,0 +1,46 @@
+---
+type: claim
+domain: health
+description: "The convergence of chart review exclusion, V28 completion, and flat rates in 2027 creates the first sustained compression of MA economics since BBA 1997"
+confidence: likely
+source: "CMS 2027 Medicare Advantage and Part D Advance Notice (2026-02-01)"
+created: 2026-03-11
+depends_on:
+  - "CMS 2027 chart review exclusion targets vertical integration profit arbitrage by removing upcoded diagnoses from MA risk scoring"
+  - "Devoted is the fastest-growing MA plan at 121 percent growth because purpose-built technology outperforms acquisition-based vertical integration during CMS tightening"
+---
+
+# CMS 2027 Advance Notice creates structural inflection for MA through chart review exclusion, V28 completion, and flat rates
+
+The 2027 Medicare Advantage rate announcement represents the most structurally significant reform year since MMA 2003 because three simultaneous changes converge to compress MA plan economics: (1) exclusion of ALL diagnoses from unlinked chart review records, projected to save >$7 billion in 2027, (2) completion of the V28 risk adjustment model phase-in with recalibration using 2023 diagnoses and 2024 expenditures, and (3) flat baseline rates that provide no growth cushion to absorb the coding compression.
+
+This is the first sustained compression of MA economics since the Balanced Budget Act of 1997, which triggered widespread plan exits. The key structural question is whether this triggers another 1997-style exit cycle or whether purpose-built MA plans have evolved sufficiently to survive where acquisition-based vertical integration models fail.
+
+## Evidence
+
+**Chart Review Exclusion:**
+- CMS proposes excluding ALL diagnoses from unlinked chart review records (not tied to documented service)
+- Diagnoses from chart reviews allowed only if tied to actual medical encounter
+- Projected savings: >$7 billion in 2027
+- This is the most targeted reform to date against retrospective code-mining
+
+**V28 Completion:**
+- 2026 is the FINAL year of V28 phase-in
+- 2027 model continues V28 clinical classification but recalibrated with newer data (2023 diagnoses, 2024 expenditures — updated from 2018/2019)
+- Notable: CKD Stage 3B and 3 now have separate coefficients (previously constrained to same value)
+
+**Industry Response:**
+- Insurers warn flat 2027 rates + chart review exclusion could drive benefit cuts and market exits
+- Combined with V28 completion, this is the most structurally significant reform year since MMA 2003
+- Purpose-built MA plans (lower coding intensity, genuine care delivery) are better positioned than acquisition-based plans
+
+## Historical Parallel
+
+The BBA 1997 created a similar compression through payment cuts that triggered widespread plan exits. The 2027 reforms differ in mechanism (coding compression rather than rate cuts) but create similar economic pressure. The outcome will test whether the MA market has structurally differentiated between purpose-built care delivery models and acquisition-based arbitrage plays.
+
+---
+
+Relevant Notes:
+- [[CMS 2027 chart review exclusion targets vertical integration profit arbitrage by removing upcoded diagnoses from MA risk scoring]]
+- [[Devoted is the fastest-growing MA plan at 121 percent growth because purpose-built technology outperforms acquisition-based vertical integration during CMS tightening]]
+- [[value-based care transitions stall at the payment boundary because 60 percent of payments touch value metrics but only 14 percent bear full risk]]

domains/health/cms-exploring-ai-powered-risk-adjustment-to-detect-upcoding-patterns-across-population-scale-data.md

@@ -0,0 +1,43 @@
+---
+type: claim
+domain: health
+description: "CMS is exploring AI-based risk adjustment that could detect upcoding patterns across millions of records, fundamentally changing the coding enforcement dynamic"
+confidence: speculative
+source: "CMS 2027 Medicare Advantage and Part D Advance Notice (2026-02-01)"
+created: 2026-03-11
+secondary_domains:
+  - ai-alignment
+---
+
+# CMS exploring AI-powered risk adjustment to detect upcoding patterns across population-scale data
+
+CMS signals in the 2027 Advance Notice that it is exploring next-generation AI-powered risk adjustment models as part of broader Star Ratings and quality measurement modernization. If implemented, AI-based risk adjustment would fundamentally change the coding enforcement game because AI can detect upcoding patterns across millions of records simultaneously—a capability that traditional audit sampling cannot match.
+
+Current risk adjustment relies on retrospective audits of small samples, which creates a cat-and-mouse game where plans optimize coding up to the audit detection threshold. AI-powered risk adjustment could shift this dynamic by analyzing population-scale patterns in real-time, making systematic upcoding detectable and unprofitable.
+
+## Evidence
+
+**CMS Signals (from 2027 Advance Notice):**
+- CMS is exploring AI-based risk adjustment as part of modernization efforts
+- Also exploring alternative data sources and timeline compression to reduce current 2-year lag between measurement and payment
+- Part of broader Star Ratings reform package including new depression screening and follow-up measure (2027 measurement year, 2029 ratings)
+
+**Structural Implications:**
+- Traditional audit sampling reviews small fractions of claims, creating optimization space for plans
+- AI could analyze 100% of claims across all plans simultaneously, detecting statistical anomalies
+- Would shift enforcement from retrospective penalty to prospective prevention
+
+## Why This Remains Speculative
+
+1. CMS has not published technical specifications or implementation timeline
+2. Implementation would require resolving significant privacy and due process questions
+3. AI model transparency and explainability requirements for regulatory use are unresolved
+4. Industry will likely challenge any AI-based adjustment methodology through administrative and legal processes
+5. Single source (CMS Advance Notice) signals exploration but not commitment
+
+---
+
+Relevant Notes:
+- [[CMS 2027 chart review exclusion targets vertical integration profit arbitrage by removing upcoded diagnoses from MA risk scoring]]
+- [[AI diagnostic triage achieves 97 percent sensitivity across 14 conditions making AI-first screening viable for all imaging and pathology]]
+- [[healthcare AI regulation needs blank-sheet redesign because the FDA drug-and-device model built for static products cannot govern continuously learning software]]

inbox/archive/2026-02-01-cms-2027-advance-notice-ma-rates.md

@@ -7,9 +7,15 @@ date: 2026-02-01
 domain: health
 secondary_domains: []
 format: report
-status: unprocessed
+status: processed
 priority: high
 tags: [cms, medicare-advantage, 2027-rates, chart-review-exclusion, star-ratings, V28, risk-adjustment]
+processed_by: vida
+processed_date: 2026-03-11
+claims_extracted: ["cms-2027-advance-notice-creates-structural-inflection-for-ma-through-chart-review-exclusion-v28-completion-and-flat-rates.md", "cms-exploring-ai-powered-risk-adjustment-to-detect-upcoding-patterns-across-population-scale-data.md"]
+enrichments_applied: ["CMS 2027 chart review exclusion targets vertical integration profit arbitrage by removing upcoded diagnoses from MA risk scoring.md", "Devoted is the fastest-growing MA plan at 121 percent growth because purpose-built technology outperforms acquisition-based vertical integration during CMS tightening.md"]
+extraction_model: "anthropic/claude-sonnet-4.5"
+extraction_notes: "Extracted two claims: (1) 2027 as structural inflection year through convergence of three reforms, rated 'likely' because it's based on official CMS policy with clear economic mechanisms and industry response; (2) AI-powered risk adjustment exploration, rated 'speculative' because CMS has only signaled exploration without technical details or timeline. Enriched two existing claims with implementation details and confirmation of structural dynamics. The BBA 1997 parallel is the key analytical frame—will 2027 trigger exits or differentiation?"
 ---
 
 ## Content
@@ -55,3 +61,10 @@ tags: [cms, medicare-advantage, 2027-rates, chart-review-exclusion, star-ratings
 PRIMARY CONNECTION: [[CMS 2027 chart review exclusion targets vertical integration profit arbitrage by removing upcoded diagnoses from MA risk scoring]]
 WHY ARCHIVED: Updates and deepens the existing KB claim with the full 2027 reform package context.
 EXTRACTION HINT: The parallel to BBA 1997 is the key analytical frame — will 2027 trigger plan exits or differentiation?
+
+
+## Key Facts
+- V28 phase-in completes in 2026, with 2027 recalibration using 2023 diagnoses and 2024 expenditures
+- CKD Stage 3B and 3 now have separate coefficients in V28 (previously constrained to same value)
+- New depression screening and follow-up measure begins 2027 measurement year, affects 2029 ratings
+- CMS exploring timeline compression to reduce current 2-year lag between measurement and payment